Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer June 18, 2024
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial June 18, 2024
Ph 3 pivotal Namodenoson HCC study recruiting in medical centers in Europe, Israel and the US June 11, 2024
FDA approves zolbetuximab BLA resubmission for 1L locally advanced unresectable or metastatic CLDN18.2+ve HER2-neg gastric or GEJ adenocarcinoma; new PDUFA: Nov 9, 2024 June 4, 2024
First Patient Dosed in trial Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC June 3, 2024
Positive Initial Interim Safety and Efficacy Results Announced from RAMP 205 Trial of Avutometinib, Defactinib, Gemcitabine and Nab-paclitaxel combo in 1L Metastatic Pancreatic Cancer May 29, 2024
First Patient Dosed in Randomized Ph 2 Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy May 29, 2024
Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer May 29, 2024
Ph 2/3 Trial of Surufatinib + Camrelizumab combo for 1L Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui Initiated May 21, 2024
WITHDRAWN: FDA withdraws accelerated approval to infigratinib for metastatic cholangiocarcinoma May 21, 2024
China CDE Clearance for Ph 3 Trial of KRAS G12C Inhibitor Glecirasib in Patients with CRC Announced May 21, 2024
Paediatric Investigation Plan Waiver Received from the European Medicines Agency for Certepetide in Pancreatic Cancer May 21, 2024
FDA Grants Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for R/R Metastatic CRC May 21, 2024
U.S. FDA Accepts and grants Priority Review of BLA for Zeno for the Treatment of NRG1+ NSCLC and PDAC May 15, 2024
Positive Ph 1/2 Data for GT-30 Trial of Personalized Therapeutic Cancer Vaccine Announced May 15, 2024
Ph 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of OS as 1L Treatment in Patients With HER2+ve Advanced Gastric/GEJ Adenocarcinoma May 7, 2024
First Dose Level found to be Generally Well-Tolerated in Ph 1b/2 Study of Ampligen and Imfinzi Combination for Late-Stage Pancreatic Cancer May 1, 2024
FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Previously-treated Patients with Metastatic or Locally Advanced Biliary Tract Tumors May 1, 2024
FDA Approves GFH925 (KRAS G12C Inhibitor) Monotherapy trial in Ph 3 Registrational Study Treating Metastatic CRC May 1, 2024
FDA approves Lutathera® for pediatric patients with gastroenteropancreatic neuroendocrine tumors May 1, 2024
Imfinzi + chemo doubled OS rate at 3 years for patients with advanced biliary tract cancer in TOPAZ-1 Ph 3 trial April 23, 2024
IND Application for the Clinical Trial of HLX53 in Combination with HANSIZHUANG Plus HANBEITAI for the 1L Treatment of Locally Advanced or Metastatic HCC Patients Approved by NMPA April 23, 2024
